La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Neuland Laboratories Bilan de santé
Santé financière contrôle des critères 6/6
Neuland Laboratories possède un total de capitaux propres de ₹12.8B et une dette totale de ₹953.9M, ce qui porte son ratio d'endettement à 7.4%. Son actif total et son passif total sont ₹18.3B et de ₹5.5B. L'EBIT de Neuland Laboratories est ₹4.3B ce qui fait que son ratio de couverture des intérêts 129.3. Elle dispose de liquidités et de placements à court terme de ₹875.8M.
Informations clés
7.4%
Ratio d'endettement
₹953.90m
Dette
| Ratio de couverture des intérêts | 129.3x |
| Argent liquide | ₹875.75m |
| Fonds propres | ₹12.83b |
| Total du passif | ₹5.50b |
| Total des actifs | ₹18.33b |
Mises à jour récentes de la santé financière
Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12
Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30Recent updates
After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Analyse de la situation financière
Passif à court terme: Les actifs à court terme de NEULANDLAB ( ₹9.2B ) dépassent ses passifs à court terme ( ₹4.3B ).
Passif à long terme: Les actifs à court terme de NEULANDLAB ( ₹9.2B ) dépassent ses passifs à long terme ( ₹1.2B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de NEULANDLAB ( 0.6% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de NEULANDLAB a été réduit de 33.1% à 7.4% au cours des 5 dernières années.
Couverture de la dette: La dette de NEULANDLAB est bien couverte par le flux de trésorerie opérationnel ( 273.8% ).
Couverture des intérêts: Les paiements d'intérêts de NEULANDLAB sur sa dette sont bien couverts par l'EBIT ( 129.3 x couverture).